美国镭学会低级别胶质瘤合理使用标准的更新：异柠檬酸脱氢酶（IDH）抑制剂的纳入
An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors.
作者信息
Tom Martin C, Nagpal Seema, Palmer Joshua D, Breen William G, Pollom Erqi L, Lehrer Eric J, McGranahan Tresa M, Shiue Kevin, Chundury Anupama, McClelland Iii Shearwood, Saeed Hina, Chang Eric L, Chiang Veronica L S, Wang Tony J C, Knisely Jonathan P S, Chao Samuel T, Milano Michael T
机构信息
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
出版信息
Radiother Oncol. 2025 Jan;202:110640. doi: 10.1016/j.radonc.2024.110640. Epub 2024 Nov 16.
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.
ARS脑委员会建议，伏立西尼可能适用于复发或残留的异柠檬酸脱氢酶（IDH）突变型2级少突胶质细胞瘤或星形细胞瘤。伏立西尼通常不适用于完全切除的2级少突胶质细胞瘤或星形细胞瘤、任何3级少突胶质细胞瘤或星形细胞瘤，或与放疗和/或化疗联合用于任何2-3级胶质瘤。
Zotero 插件